SETTING: Two tuberculosis hospitals in the United States. OBJECTIVE: To determine the population pharmacokinetic (PK) parameters of ofloxacin following multiple oral doses. DESIGN: A total of 73 patients with tuberculosis (TB) participated in the study. Subjects received multiple doses of ofloxacin as part of their treatment. They also received concurrent medications based on in vitro susceptibility data. Serum samples were collected over 10 h and assayed by a validated high performance liquid chromatography (HPLC) assay. Concentration-time data were analyzed using population methods. RESULTS: Ofloxacin concentrations increased linearly with increasing oral doses. Delayed absorption was seen at least once in 29% of patients. Ofloxacin elimination decreased with declining renal function and increasing age. Higher daily doses were well tolerated, and appeared to maximize the peak concentration to minimal inhibitory concentration ratio (Cmax:MIC). CONCLUSION: Ofloxacin PK parameters were comparable to those previously published for other patient populations. Higher daily doses may offer pharmacodynamic advantages for the treatment of TB.
SETTING: Two tuberculosis hospitals in the United States. OBJECTIVE: To determine the population pharmacokinetic (PK) parameters of ofloxacin following multiple oral doses. DESIGN: A total of 73 patients with tuberculosis (TB) participated in the study. Subjects received multiple doses of ofloxacin as part of their treatment. They also received concurrent medications based on in vitro susceptibility data. Serum samples were collected over 10 h and assayed by a validated high performance liquid chromatography (HPLC) assay. Concentration-time data were analyzed using population methods. RESULTS:Ofloxacin concentrations increased linearly with increasing oral doses. Delayed absorption was seen at least once in 29% of patients. Ofloxacin elimination decreased with declining renal function and increasing age. Higher daily doses were well tolerated, and appeared to maximize the peak concentration to minimal inhibitory concentration ratio (Cmax:MIC). CONCLUSION:Ofloxacin PK parameters were comparable to those previously published for other patient populations. Higher daily doses may offer pharmacodynamic advantages for the treatment of TB.
Authors: S Thee; A J Garcia-Prats; H M McIlleron; L Wiesner; S Castel; J Norman; H R Draper; P L van der Merwe; A C Hesseling; H S Schaaf Journal: Antimicrob Agents Chemother Date: 2014-02-18 Impact factor: 5.191
Authors: Carlton K K Lee; Michael P Boyle; Marie Diener-West; Lois Brass-Ernst; Michelle Noschese; Pamela L Zeitlin Journal: Chest Date: 2007-03 Impact factor: 9.410
Authors: Charles A Peloquin; David Jamil Hadad; Lucilia Pereira Dutra Molino; Moises Palaci; W Henry Boom; Reynaldo Dietze; John L Johnson Journal: Antimicrob Agents Chemother Date: 2007-12-10 Impact factor: 5.191
Authors: Emmanuel Chigutsa; Sandra Meredith; Lubbe Wiesner; Nesri Padayatchi; Joe Harding; Prashini Moodley; William R Mac Kenzie; Marc Weiner; Helen McIlleron; Carl M J Kirkpatrick Journal: Antimicrob Agents Chemother Date: 2012-05-07 Impact factor: 5.191
Authors: Simbarashe P Zvada; Paolo Denti; Frederick A Sirgel; Emmanuel Chigutsa; Mark Hatherill; Salome Charalambous; Stanley Mungofa; Lubbe Wiesner; Ulrika S H Simonsson; Amina Jindani; Thomas Harrison; Helen M McIlleron Journal: Antimicrob Agents Chemother Date: 2013-11-04 Impact factor: 5.191
Authors: Anthony J Garcia-Prats; Heather R Draper; Stephanie Thee; Kelly E Dooley; Helen M McIlleron; James A Seddon; Lubbe Wiesner; Sandra Castel; H Simon Schaaf; Anneke C Hesseling Journal: Antimicrob Agents Chemother Date: 2015-07-20 Impact factor: 5.191